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Largeandrarecopynumbervariants(CNVs)atseverallocihavebeenshowntoincreaseriskforschizophrenia.
Aiming to discover novel susceptibility CNV loci, we analyzed 6882 cases and 11255 controls genotyped on
Illumina arrays, most of which have not been used for this purpose before. We identiﬁed genes enriched for
rare exonic CNVs among cases, and then attempted to replicate the ﬁndings in additional 14 568 cases and 15
274 controls. In a combined analysis of all samples, 12 distinct loci were enriched among cases with nominal
levelsofsigniﬁcance(P < 0.05);however,nonewouldsurvivecorrectionformultipletesting.Theselociinclude
recurrentdeletionsat16p12.1,alocuspreviouslyassociatedwithneurodevelopmentaldisorders(P 5 0.0084in
thediscoverysampleandP 5 0.023inthereplicationsample).Otherplausiblecandidatesincludenon-recurrent
deletions at the glutamate transporter gene SLC1A1, a CNV locus recently suggested to be involved in schizo-
phreniathroughlinkageanalysis,andduplicationsat1p36.33andCGNL1.Aburdenanalysisoflarge(>500 kb),
rareCNVsshoweda1.2%excessincasesafterexcludingknownschizophrenia-associatedloci,suggestingthat
additional susceptibility loci exist. However, even larger samples are required for their discovery.
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Copy number variants (CNVs) at several loci are now robustly
associated with schizophrenia (1–7). The majority of these are
ﬂankedbylowcopyrepeats(LCRs) whichmediate theirforma-
tion through non-allelic homologous recombination (NAHR).
Therefore, these CNVs occupy the same genomic locations
(i.e. they are recurrent). In addition to these recurrent CNVs,
two genes, NRXN1 and VIPR2, have also been associated with
schizophrenia when disrupted by non-recurrent CNVs with dif-
ferent breakpoints (8–10). All strongly implicated CNV loci in
schizophrenia are rare, CNVs at each locus being found in
0.082–0.59% of cases and even less often in controls (5,6).
Due to their rarity, very large sample sizes have been required
to identify these loci. For example, the latest CNV locus asso-
ciated with schizophrenia, a duplication of the Williams–
Beuren region, was identiﬁed with a sample of over 14 000
cases and28000 controls(11).Itislogicalthatfurthersuscepti-
bilitylociexist,buthavesofarescapedidentiﬁcationduetotheir
rarity or lower penetrance.
Moststronglyassociated schizophreniaCNVs areimplicated
inotherneuropsychiatricdisorders,suchasautismspectrumdis-
order(ASD),attentiondeﬁcithyperactivitydisorder,intellectual
disability (ID) and developmental delay (DD) (12–14). There
are also many further CNVs that increase susceptibility for ID/
DD/ASD(14)thathavenotbeenassociatedwithschizophrenia.
Thiscouldalsobeduetopowerlimitations:currentCNVstudies
inID/DDhavebeenmuchlargerthaninschizophrenia(5,14)and
the rate of these CNVs in schizophrenia is usually lower than in
ID/DD(15),makingtheirdiscoveryevenharder.Therefore,itis
possible that some additional CNVs that are enriched in ID/DD
willalsoincreaseriskforschizophrenia,iftestedinmuchlarger
samples.
Wereasonedthatthebestwaytodiscovernovelschizophrenia
susceptibility loci is by using new, very large schizophrenia
samples. We ﬁrst examined rare CNVs in a discovery sample
of 6882 cases and 11 255 controls. These cases and most of the
controls have not been used before for the discovery of new
loci, except the WTCCC2 subset of the control sample which
ﬁgures in several papers and most meta-analyses. Loci that
showed evidence for association were followed up in the add-
itional 14 568 cases and 15 274 controls, bringing the total
number of samples analyzed to  48 000.
RESULTS
Novel candidate CNV loci
Eachgeneinthegenomewasexaminedforexon-disruptingCNVs
in cases and controls. After excluding genes within previously
implicated loci (13 loci ﬂanked by LCRs, and two individual
genes, NRXN1 and VIPR2, listed in Supplementary Material,
TableS3),genesin37regions(containing72genes)wereenriched
among our discovery cases with nominal levels of signiﬁcance
(two-sided Fisher’s exact P , 0.05, Supplementary Material,
TablesS5andS6).Weremovedfourregionsfromsubsequentana-
lyses after manual inspection of their Z-scores, Log R ratio and
B-allelefrequencytracesfoundthemtobeunreliable.Thesigniﬁ-
cancefornoneofthegeneswouldsurviveaconservativeBonfer-
roni correctionformultipletestingof 20000genes separately for
deletions and duplications (P , 1.25 × 10
26). Restricting the
analysis to only individuals of European ancestry ( 90% of
the sample) did not change these results (data not presented). In
thereplicationdata,CNVsofthesametype(deletionsorduplica-
tions)at 20of the 33 loci were more common among cases (Sup-
plementary Material, Table S5) but only one (16p12.1) was
nominally signiﬁcant (without multiple-testing correction). In a
combined analysis of the discovery and replication samples,
genes in 12 distinct regions remained signiﬁcant (Cochran–
Mantel–Haenszel (CMH) P , 0.05, Table 1).Again, the signiﬁ-
cancefornoneofthesegeneswouldsurvivegenome-widecorrec-
tion for multiple testing.
Weﬁndthebestevidenceforthefollowingloci(detailsinthe
Supplementary Material):
Deletionsat16p12.1arethemostlikelyﬁndingasitistheonly
locus signiﬁcant in the replication dataset on its own and is a
known pathogenic locus associated with ID/DD/ASD (14,16).
It includes seven genes disrupted by recurrent deletions
ﬂankedbyLCRs(SupplementaryMaterial,Fig.S13).Inourdis-
coverysample,thedeletionwasfoundin13casesand6controls
(0.19 versus 0.053%, two-sided Fisher’s exact P ¼ 0.0084). In
our replication sample, the deletion was found in a further 20
cases and 9 controls (0.14 versus 0.059%, one-sided Fisher’s
exact P ¼ 0.023). A combined analysis of all data found the de-
letion in 0.15% of cases and 0.057% of controls, CMH P ¼
0.0016, odds ratio (OR) ¼ 2.72, 95% conﬁdence interval
(95%CI) ¼ 1.48–5.02 (Table 1).
Our most signiﬁcant ﬁnding involves non-recurrent duplica-
tions of ﬁve genes at 1p36.33 (GNB1, CALML6, TMEM52,
KIAA1751, GABRD), which partially overlap another known
pathogenic locus when deleted: 1p36 (17,18). In the combined
data, duplications are found in 0.065% of cases and 0.0075%
of controls, CMH P ¼ 0.00050, OR ¼ 8.66, 95%CI ¼ 1.97–
38.12 (Table 1). As these non-recurrent CNVs have different
breakpoints, the ﬁve genes have slightly different CNV counts
(Supplementary Material, Fig. S3 and Table S5).
The strongest single gene region is CGNL1 (chr15:57.67–
57.84 Mb). In the combined data, CGNL1 duplications are found
in 0.32% of cases and 0.19% of controls, CMH P ¼ 0.0019,
OR ¼ 1.71, 95%CI ¼ 1.19–2.46 (Table 1 and Supplementary
Material, Fig. S12).
Another good single gene candidate is the glutamate trans-
porter SLC1A1, where analysis of all data found deletions in
0.047% of cases and 0.0075% of controls, CMH P ¼ 0.0098,
OR ¼ 6.19, 95%CI ¼ 1.36–28.24 (Table 1 and Supplementary
Material, Fig. S11).
Burden analysis
An increased burden of large, rare CNVs is well established in
schizophrenia (2,7). To determine how much of this excess is
explained by already implicated loci, we performed a CNV
burdenanalysisinourdiscoverysamplewithandwithoutthein-
clusionoflociimplicatedinthecurrentstudy(regionsinTable1)
and 15 loci from previous studies (Supplementary Material,
Table S3). There is a 2.5% excess of all CNVs .500 kb in
cases, of which 1.3% is accounted for by already implicated
loci(Fig.1andSupplementaryMaterial,TableS3).Theremain-
ing 1.2% excess in cases comes mostly from deletions .1M b ,
and from duplications .500 kb (details in Supplementary
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Table 1. Novel candidate CNV loci
Locus/gene Location (Mb) Type Discovery
(case/control)
Replication
(case/control)
Discovery P
(two-sided
Fisher)
Replication P
(one-sided
Fisher)
Combined P
(CMH)
Totals %
case/control
Odds ratio (95%CI)
1p36.33 (GNB1, CALML6,
TMEM52, KIAA1751, GABRD)
chr1:1.85–2.11 Dup 9/0 (0.13%/0%) 5/2 (0.034%/0.013%) 0.00016 0.21 0.0005 0.065%/0.0075% 8.66 (1.97–38.12)
AQP12A, KIF1A chr2:241.63–241.75 Dup 51/39 (0.74%/0.35%) 23/25 (0.16%/0.16%) 0.00042 0.61 0.0028 0.34%/0.24% 1.43 (1.02–2.00)
ELOVL6 chr4:110.97–111.12 Dup 4/0 (0.058%/0%) 3/1(0.021%/0.0065%) 0.021 0.29 0.024 0.033%/0.0038% 8.66 (1.07–70.39)
FAM149A, FLJ38576,
CYP4V2
chr4:187.05–187.14 Dup 9/0 (0.13%/0%) 1/3 (0.0069%/0.02%) 0.00016 0.93 0.02 0.047%/0.011% 4.12 (1.13–14.99)
TRIML1, TRIML2 chr4:189.01–189.07 Del 8/3 (0.12%/0.027%) 4/2 (0.027%/0.013%) 0.026 0.32 0.024 0.056%/0.019% 2.97 (1.05–8.43)
IRGM, ZNF300, SMIM3 chr5:150.16–150.30 Del 4/0 (0.058%/0%) 5/1(0.034%/0.0065%) 0.021 0.099 0.015 0.042%/0.0038% 11.14 (1.41–87.90)
PHACTR2 chr6:144–144.15 Dup 5/1 (0.073%/0.0089%) 5/2 (0.034%/0.013%) 0.032 0.21 0.03 0.047%/0.011% 4.12 (1.13–14.99)
GLIS3 chr9:3.82–4.3 Del 5/0 (0.073%/0%) 2/0 (0.014%/0%) 0.0079 0.24 0.0084 0.033%/0% NA (1.06–324.96)
SLC1A1 chr9:4.49–4.59 Del 6/1 (0.087%/0.0089%) 4/1(0.027%/0.0065%) 0.014 0.17 0.0098 0.047%/0.0075% 6.19 (1.36–28.24)
CGNL1 chr15:57.67–57.84 Dup 35/25 (0.51%/0.22%) 34/25 (0.23%/0.16%) 0.0019 0.11 0.0019 0.32%/0.19% 1.71 (1.19–2.46)
16p12.1 (7 genes) chr16:21.95–22.43 Del 13/6 (0.19%/0.053%) 20/9 (0.14%/0.059%) 0.0084 0.023 0.0016 0.15%/0.057% 2.72 (1.48–5.02)
GALR1 chr18:74.96–74.98 Dup 5/0 (0.073%/0%) 0/0 (0%/0%) 0.0079 1 0.016 0.023%/0% NA (0.75–246.1)
Discovery ¼ 6882casesand11255controls.Replication ¼ 14568casesand15274controls.CMH ¼ Cochran–Mantel–Haenszeltest.Type:Dup ¼ duplicationsandDel ¼ deletion.CI ¼ conﬁdenceinterval.
Fisher ¼ Fisher’sexacttest.ThecolumnsfordiscoveryandreplicationdatasetsdisplaythenumbersofCNVsthatintersectexonsinthegene(orthegenewiththestrongestP-valueinregionsthatcontainmultiple
genes) and the % of cases and controls affected by these CNVs.
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1analysis before and after removing schizophrenia-associated
CNVs. We found that of the 2.5% excess of all CNVs .500 kb
in cases, 1.3% comes from loci implicated in the current (0.2%)
and previously published studies (1.1%). As our discovery
sample has 80% power to detect around half of the previously
implicated CNVs (Fig. 2), we speculate that the remaining 1.2%
excessyettobediscoveredforCNVs .500 kbwillbeattributed
to CNVs with lower population frequencies and/or smaller ORs
than those already identiﬁed. These will therefore require even
larger samples for their discovery, but some are likely to be just
singleton observations, where association analysis will fail. We
feel that burden analysis of CNVs smaller than 500 kb, even on
thehigh-qualityarraysweused,isstill subjectedtotoo manypo-
tential biases to be reliable (unlike selected individual loci, that
can be inspected further, see Materials and Methods and
Results), and we are unable to speculate about the precise
excess of smaller CNVs. We expect such loci should also exist,
but might also have lower ORs and/or frequencies.
Schizophrenia has a high heritability (81% according to the
largest review of twin studies) (20). CNVs probably contribute
to this heritability; however, they can explain only a small
part of it. Our results suggest that only 2.5% of patients (versus
1% of controls) carry a conﬁrmed schizophrenia-associated
CNV (Supplementary Material, Table S3), with an additional
1.2% excess burden of large CNVs (Fig. 1). Not all of these
would contribute to heritability, as some 16% of the .500 kb
CNVs occur de novo (21) as do 9–80% of those at speciﬁc
schizophrenia-associated loci (15,22). In addition, their
penetranceisnotcomplete(15),whichwouldlowertheircontribu-
tion to heritability. We cannot speculate on the extent of the con-
tribution of smaller CNVs, but no doubt they contribute as well.
Deletions at 16p12.1
Although we found no novel genome-wide signiﬁcant associa-
tions, we report deletions at 16p12.1 as the most likely new
risk locus. This deletion has previously been observed in a
schizophrenia cohort (16), but that study lacked the statistical
powertoimplicateit.Hereweshowfortheﬁrsttimeenrichments
with nominal levels of signiﬁcance in both our discovery and
replication cases, resulting in a combined P-value of 1.6 ×
10
23.Thedeletionhasthehallmarksofalmostallrobustlyasso-
ciated CNVs, in that it is recurrent, is ﬂanked by LCRs, disrupts
multiple genes and is a susceptibility locus for developmental
disorders (15,16). The clinical features previously associated
with 16p12.1 deletions include DD, speech delay, epilepsy and
craniofacial and skeletal abnormalities (16). 16p12.1 deletions
are found in 0.2% of ID/DD patients (16) and we observe them
in 0.15% of schizophrenia cases and 0.057% of controls. The
combination of a modest OR (OR ¼ 2.72) for developing
schizophrenia and a low frequency could explain why it has
not been identiﬁed until now (our discovery sample has ,80%
power to detect its association at a 0.05; Fig. 2).
Around a quarter of ID/DD patients with a 16p12.1 deletion
alsocarryanadditionalpathogenicCNV(deﬁnedasaCNVasso-
ciated with ID/DD or .500 kb) (15,16) and in those that do so,
the phenotype is more severe (16). In our discovery sample we
found only 1 of 13 cases to also carry an additional pathogenic
CNV (a 15q11.2 deletion) and none out of the six controls. Al-
though this lower rate is not statistically signiﬁcant compared
with the ID/DD data, it is plausible that individuals with a
second hit are more likely to have ID/DD, while those with
onlythe 16p12.1deletion are moreat riskofdeveloping schizo-
phrenia (23). A structural polymorphism with two conﬁgura-
tions is known to affect the orientation of LCRs that mediate
the formation of 16p12.1 deletions (23,24). Individuals with
themorecommonconﬁgurationhaveLCRsindirectorientation
(23,24), which is a mechanistic requirement for NAHR to form
deletions.Asthisriskconﬁgurationisfoundatdifferentfrequen-
cies across European (83%), African (98%) and Asian popula-
tions (72%), there is a potential for population stratiﬁcation to
bias 16p12.1 associations (23,24). However, when we restrict
our analysis to individuals of European decent, the deletion
shows even greater enrichment (13/6307 cases, 5/10 676 con-
trols, two-sided Fisher’s exact P ¼ 0.0029).
1p36.33 duplications
The ﬁve genes disrupted by duplications in 0.065% of cases and
0.0075% of controls (CMH P ¼ 0.0005) are located within
1.8 Mb of the 10 Mb 1p36 deletion syndrome region, a known
pathogenic locus for ID/DD when deleted (17,18) .T h eg e n ew i t h
the strongest P-value in this region is KIAA1751 (P ¼ 0.0005),
but it is uncharacterized. A more likely candidate is the gamma-
aminobutyric acid (GABA) A receptor, delta (GABRD)( S u p p l e -
mentaryMaterial,Fig.S3andTableS5)whichhasbeensuggested
to be responsible for the neuropsychiatric characteristics seen in
1p36 deletion patients as it is highly expressed in brain and
Figure 2. Discovery sample power calculation. The curve represents the point
above which our discovery sample had 80% power to detect associations at
alpha0.05.Thex-axisindicatesthefrequencyoftheCNVincontrols,onalogarith-
micscale(e.g. 24.0equatestoarateofoneCNVper10000people).They-axisis
theORforincreasingrisktodevelopschizophrenia.Forreferenceweindicatethe
pointsforpreviouslyimplicatedloci.FrequenciesandORsarefromMalhotraand
Sebat (5), except for NRXN1 (4,8); 16p11.2 distal deletion (1) and Williams–
Beuren syndrome duplication (11). For the 22q11.2 deletion, there have been no
carriers reported among 70739 controls, leading to a frequency of 0% and
OR ¼ inﬁnity. In order to ﬁt more realistic data points into the ﬁgure, we added
one carrier in controls and scaled down the OR to 99, as no factor can increase
the risk for a disease with a population frequency of 1% by more than 100-fold.
1672 Human Molecular Genetics, 2014, Vol. 23, No. 6functions as a subunit of GABA-A receptors (25). Another prom-
ising candidate is GNB1, a member of the previously implicated
N-methyl-D-aspartic acid (NMDAR) gene pathway (26). It is
also possible that the disruption of all ﬁve genes increases risk
for SCZ.
CGNL1 duplication
Our strongest statistical result for CNVs hitting a single gene
involves duplications of cingulin-like 1 (CGNL1), where we
ﬁnd exons disrupted in 0.32% of cases and 0.19% of controls
(CMH P ¼ 0.0019). The duplications are mostly identical in
size and do not cover the whole gene (Supplementary Material,
Fig. S12). CGNL1 is found at adherent junctions and tight cell–
cell junctions and coordinates junction assembly via Rac1 and
RhoA GTPases (27,28). In the case–control analysis by Levin-
son et al.( 4), duplications of this gene were reported as having
suggestive evidence for association with schizophrenia, but
this was only presented in their Supplemental Material. That
study used the Molecular Genetics of Schizophrenia (MGS)
and International Schizophrenia Consortium (ISC) cohorts,
similar to our replication sample.
SLC1A1 deletions
SLC1A1 encodes a high-afﬁnity glutamate transporter respon-
sible for inactivating synaptic glutamate and preventing extra-
cellular levels of glutamate from reaching neurotoxic levels
(29). Glutamate acts on NMDAR receptors, and a large body
of evidence has associated NMDAR dysfunction with schizo-
phrenia (30). We ﬁnd non-recurrent exonic deletions in
0.047% of cases and 0.0075% of controls (CMH P ¼ 0.0098).
Recently, Myles-Worsley et al.( 31) reported a deletion of this
gene to co-segregate with schizophrenia and bipolar schizo-
affective disorder in a ﬁve-generation family, reaching a lod-
score of 3.64. To our knowledge, this is the ﬁrst time a CNV
linkage association has received support from a large case–
control analysis in schizophrenia. Additional observations of
SLC1A1deletionsindiseasecohortsincludeoneexonicdeletion
in235subjectswithbothSCZandepilepsy(32),asingleexonic
deletion in 459 unrelated adults with schizophrenia (33), one
exonic deletion among 1637 German patients with schizophre-
nia or schizoaffective disorder (34) and Cooper et al.( 17)
report an enrichment of SLC1A1 deletions in neurological, cra-
niofacial and epilepsy cases.
In conclusion, we have used a large sample of patients and
controls to discover new CNV susceptibility loci. This sample
has the power to detect on its own a large proportion of the pre-
viously associated CNV loci (Fig. 2 and Supplementary Mater-
ial,TableS3).Wesuggestaroleforanadditional12newloci,but
only one of these was signiﬁcant in our replication sample, and
even that result does not withstand correction for multiple
testing. Therefore, these results need independent conﬁrmation
infurtherlargesamples.Excludinglocithatarealreadystrongly
implicated, an excess burden of large and rare CNVs remains in
cases, indicating that there are likely to be further susceptibility
genes disrupted by CNVs, but these will be of smaller effect
size, or very rare, so would require even larger samples to be
identiﬁed.
MATERIALS AND METHODS
‘The discovery sample’ consisted of 7129 schizophrenic cases
(prior to quality control (QC) ﬁltering) from the CLOZUK
(N ¼ 6558) and the CardiffCOGS (N ¼ 571) samples, which
have been previously described (6,15,35) but have not yet con-
tributed to any analysis aimed at identifying new CNV loci.
Brieﬂy,theCLOZUKsampleconsistsofpatientstakingtheanti-
psychotic clozapine, a drug reserved in the UK for patients that
have not responded to trials of at least two other antipsychotics.
Toallowforearlydetectionofneutropaeniathatcanresultfrom
treatmentwithclozapine,patientsarerequiredtoprovideregular
blood samples. Through collaboration withNovartis, the manu-
facturer of a proprietary form of clozapine (Clozaril), we
acquired anonymized DNA samples from people with schizo-
phrenia who were taking the drug. Approval by the local ethics
committeewasgrantedfortheuseofthesesamplesingeneticas-
sociation studies. Patients are aged 18–90, had arecorded diag-
nosis of treatment resistant schizophrenia, and 71% are male. A
highermaleratioisnotunusualforsamplesrecruitedforgenetic
studiesinschizophrenia:thisproportionis66%intheISCstudy
(2)and70%intheMGSstudy(4).TheCardiffCOGSisasample
of clinically diagnosed schizophrenia patients from the UK.
Interview with the SCAN instrument (36) and case note review
wasusedtoarriveatabest-estimatelifetimediagnosisaccording
to DSM-IV criteria (37). All discovery cases were genotyped at
the Broad Institute, Stanley Centre for Psychiatric Research,
USA on either Illumina OmniExpress or OmniCombo arrays.
Thediscoverycontrolcohortconsistedoffourpubliclyavail-
able, non-psychiatric datasets, totaling 12 080 samples prior to
QC (Supplementary Material, Table S2). These datasets were
chosen as they were genotyped on Illumina arrays similar to
those used for the cases: Illumina Human Omni2.5, Illumina
HumanOmni1_Quad or Illumina 1.2M. Further details of these
samples are provided in the Supplementary Material.
CNV calling and QC
Principalcomponentanalysiswasperformedtoderiveethnicities
of discovery samples. Identity by decent was performed to iden-
tify and remove duplicate individuals. For each case and control
dataset,LogRRatios(LRR)andB-allelefrequenciesweregener-
ated using Illumina Genome Studio software (v2011.1) and used
to call CNVs with PennCNV (38). CNV calling was performed
following the standard protocol and adjusting for GC content.
Toavoidacross-platformCNVlocusdetectionbiasinthediscov-
ery sample, we called CNVs using a consensus set of 520766
probes that are present on all microarrays used. Samples were
excludediftheywerefoundtobeanoutlierforanyoneofthefol-
lowing QC metrics: LRR standard deviation, B-allele frequency
drift, wave factor and total number of CNVs called per person.
The numbers of discovery cases and controls that passed QC are
presented in Table 2. All coordinates in this paper are according
to UCSC build 37, hg19.
CNVs from samples that passed QC were joined together if
the distance separating them was ,50% of their combined
length using an in-house developed open source program
(http://x004.psycm.uwcm.ac.uk/~dobril/combine_CNVs/). CNVs
were then excluded if they were either ,10 kb, covered by
,10 probes, overlapped with LCRs by .50% of their length
Human Molecular Genetics, 2014, Vol. 23, No. 6 1673or had a probe density of ,1 SNP/20 kb. CNV loci with a fre-
quency .1% in all samples were excluded using PLINK (39).
Finally, all CNVs were validated by the in silico median
Z-score outlier method, described in detail elsewhere (26) and
in the Supplementary Material. Brieﬂy, this method uses the
median value of all normalized LRR probe intensities within a
CNV to assess copy number. All CNVs in regions enriched
among cases in our Discovery sample that passed our ﬁltering
criteria are available in Supplementary Material, Table S6.
‘Replication samples’ consisted of six independent case/
control datasets and one trio dataset, totaling of 14 568 cases
and 15 274 controls after QC: MGS (4), split for samples with
a European American or African American ancestry; Inter-
national Schizophrenia Consortium (2); Bulgarian trios (BG
trios) (26); Irish (40); Swedish (41); and African American
from the Genomic Psychiatry Cohort in the United States (42).
Bulgarian probands from the BG trios sample were excluded
from the ISC sample, and the Swedish sample does not include
individualswhowerepartoftheISC.Thenumberofreplication
samples that passed QC and the arrays they were genotyped on
are presented in Table 2. Further details on genotyping and QC
of these datasets are presented in the Supplementary Material.
Statistical analysis
To identify novel risk loci we adopted a gene-based approach.
Each gene in the genome was examined for exon-disrupting
CNVs using refseq gene coordinates (downloaded from the
UCSCgenomebrowser,includesnon-codingRNAs).Deletions
and duplications were counted and analyzed separately. Genes
that reached nominal levels of signiﬁcance in the discovery
sample with a two-sided Fisher’s exact test (P , 0.05) were
furtheranalyzedwithaone-sidedFisher’sexacttestintherepli-
cation data. The combined sample of all available data was
analyzed with a CMH test, stratiﬁed by dataset: discovery
sampleasasingledatasetandeachofthesevenreplicationdata-
sets as separate samples, as shown in Table 2 (the MGS sample
was split for ethnicity). This gene-wise approach can capture
signal from both single gene enrichments, such as NRXN1 dele-
tions, and larger recurrent events through contiguous gene
enrichments.
The burden of large and rare CNVs in cases versus controls
was evaluated with a one-sided test and 10000 permutations
using PLINK (39). The analysis was stratiﬁed by CNV size
(.500,500–1and .1 Mb)andCNVtype(allCNVs,deletions
only and duplications only). All CNVs .500 kb used in the
burden analysis are listed in Supplementary Material, Table S7.
Inordertodeterminetheeffectsizeandpopulationfrequencyof
CNVsthatourdiscoverysamplehad80%powertodetectwithan
a of 0.05 (Fig. 2), we used an online open source genetic power
calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/) (43).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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